Literature DB >> 8421422

Implications of positive surgical margins.

J R Jacobs1, K Ahmad, R Casiano, D E Schuller, C Scott, G E Laramore, M al-Sarraf.   

Abstract

The recently concluded Head and Neck Intergroup trial tested the addition of three courses of cis-platinum containing chemotherapy to standard treatment of surgery and postoperative radiotherapy for patients with advanced operable squamous cell carcinoma of the head and neck. Only patients with negative surgical margins were eligible for the trial. One hundred twelve patients with positive surgical margins were dropped from the trial but continued to be followed. These patients received a variety of treatments. Positive surgical margins were most often seen in nonglottic primaries and with increasing frequency as the N stage increased. Patients with positive margins who achieved a complete clinical response to subsequent treatment had a median survival of 33.8 months vs. 9.1 months for those with less than a complete clinical response. The addition of chemotherapy did not significantly alter the median survival of the positive margin patients.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8421422     DOI: 10.1288/00005537-199301000-00012

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  12 in total

1.  Intraoperative consultation (IOC) in mucosal lesions of the upper aerodigestive tract.

Authors:  Bruce M Wenig
Journal:  Head Neck Pathol       Date:  2008-07-15

Review 2.  Molecular predictors of clinical outcome in patients with head and neck squamous cell carcinoma.

Authors:  Giovana R Thomas; Hari Nadiminti; Jacinto Regalado
Journal:  Int J Exp Pathol       Date:  2005-12       Impact factor: 1.925

3.  Extended and standard supraglottic laryngectomies: a review of 110 patients.

Authors:  Jean-Michel Prades; Pierre-Gilles Simon; Andrei P Timoshenko; Jean-Marc Dumollard; Thierry Schmitt; Christian Martin
Journal:  Eur Arch Otorhinolaryngol       Date:  2005-11-19       Impact factor: 2.503

Review 4.  Contemporary Approach to Locally Advanced Oral Cavity Squamous Cell Carcinoma.

Authors:  Christopher M K L Yao; Edward I Chang; Stephen Y Lai
Journal:  Curr Oncol Rep       Date:  2019-11-07       Impact factor: 5.075

5.  Functional laryngeal surgery - critical determinants of successful rehabilitation.

Authors:  A M Shenoy; M N Harindra; B S Premalatha; S Subbaiah; D S Reddy; A V Hari Prasad; R S
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2000-10

6.  Neoadjuvant chemotherapy: does it have benefits for the surgeon in the treatment of advanced squamous cell cancer of the oral cavity?

Authors:  Lajos Olasz; József Szalma; Eniko Orsi; Tamás Tornóczky; Tamás Markó; Zoltán Nyárády
Journal:  Pathol Oncol Res       Date:  2009-09-12       Impact factor: 3.201

7.  Disease control and clinicopathological prognostic factors of total pharyngolaryngectomy for hypopharyngeal cancer: a single-center study.

Authors:  Go Omura; Mizuo Ando; Yuki Saito; Kenya Kobayashi; Tatsuya Yamasoba; Takahiro Asakage
Journal:  Int J Clin Oncol       Date:  2014-05-30       Impact factor: 3.402

8.  Expression of p53, p21(CIP1/WAF1) and eIF4E in the adjacent tissues of oral squamous cell carcinoma: establishing the molecular boundary and a cancer progression model.

Authors:  Yi Li; Bo Li; Bo Xu; Bo Han; Hui Xia; Qian-Ming Chen; Long-Jiang Li
Journal:  Int J Oral Sci       Date:  2015-09-14       Impact factor: 6.344

9.  Treatment results and prognostic factors of patients undergoing postoperative radiotherapy for laryngeal squamous cell carcinoma.

Authors:  Ting Jin; Wei-Han Hu; Li-Bing Guo; Wen-Kuan Chen; Qiu-Li Li; Hui Lin; Xiu-Yu Cai; Nan Ge; Rui Sun; Si-Yi Bu; Xin Zhang; Meng-Yao Qiu; Wei Zhang; Su Luo; Yi-Xin Zhou
Journal:  Chin J Cancer       Date:  2011-07

10.  Close margins in oral cancers: implication of close margin status in recurrence and survival of pT1N0 and pT2N0 oral cancers.

Authors:  Sandhya Gokavarapu; Ravi Chander; Nagendra Parvataneni; Sreenivasa Puthamakula
Journal:  Int J Surg Oncol       Date:  2014-11-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.